Eli Lilly announced Q3 revenue of USD 17.6 billion representing 54% year-on-year (YoY) growth, with the 9-month total reaching USD 45.9 billion driven by tirzepatide sales of USD 24.8 billion and abemaciclib contributing USD 4.1 billion. The company leads pharmaceutical revenue rankings among the eight multinational companies reporting Q3 results, with the US market contributing USD 30.6 billion followed by Europe at USD 8.5 billion and China at USD 1.5 billion. Lilly's GLP-1 receptor agonist market share expanded to 57.9% versus Novo Nordisk's 41.7% in US prescription volume.

Pipeline advancements include six completed Phase III trials for oral GLP-1 agonist orforglipron and an imminent new drug application (NDA), as well as tirzepatide meeting its primary endpoint in a paediatric type 2 diabetes (T2D) study. The company discontinued a Phase II P2X7 inhibitor programme for pain and a Phase III abemaciclib trial in sequenced metastatic breast cancer, while advancing triple agonist retatrutide in a knee osteoarthritis pain study. Full-year revenue guidance raised to USD 63.0 to 63.5 billion, reflecting continued demand growth for incretin therapies and oncology portfolio expansion.

According to PharmCube's NextBiopharm® database, Lilly currently has nearly 50 assets nearing regulatory submission. Click here to request a free trial for NextBiopharm®.